Publication Name	World Journal of Gastroenterology
Manuscript ID	91371
Country	Greece

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Combination treatment of inflammatory bowel disease: Present status and future perspectives
Manuscript Source	Invited Manuscript
All Author List	John K Triantafillidis, Constantinos G Zografos, Manousos M Konstadoulakis and Apostolos E Papalois
Funding Agency and Grant Number
Corresponding Author	John K Triantafillidis, PhD, N/A, Inflammatory Bowel Disease Unit, "Metropolitan General" Hospital, 264 Mesogeion Avenue, Holargos 15562, Attica, Greece. jktrian@gmail.com
Key Words	Biologics for immune-mediated conditions; Dual-targeted treatment; Combination treatment; Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis
Core Tip	During the last few years, the combination of two biological agents or a combination of a biological agent and another drug belonging to the category of so-called "small molecules" seems to be steadily gaining ground [dual biologic therapy (DBT)]. Even the combination of a biological agent with a drug belonging for example to the category of immunosuppressants is a therapeutic option that has been applied for several years [combination therapy (CT)]. Finally, in daily clinical practice, various combinations of so-called first-line drugs (mesalazine, corticosteroids, antibiotics, probiotics, etc.) are used with satisfactory results in most cases. DBT and CT currently find application in cases of patients resistant to treatment or patients with extraintestinal manifestations that do not respond satisfactorily to classical treatment. The existing data, although encouraging, are not sufficient in terms of the number of patients included so far. The safety of this emerging kind of treatment is another point of interest. Finally, there is a need to carry out more studies regarding this interesting field of research.
Citation	Triantafillidis JK, Zografos CG, Konstadoulakis MM, Papalois AE. Combination treatment of inflammatory bowel disease: Present status and future perspectives. World J Gastroenterol 2024; 30 (15)：2068-2080

Received	2023-12-27 15:20
Peer-Review Started	2023-12-28 01:36
To Make the First Decision
Return for Revision	2024-01-16 08:12
Revised	2024-02-20 01:39
Second Decision	2024-03-28 01:54
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2024-03-28 02:38
Articles in Press	2024-03-28 02:38
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-04-11 01:18

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com